Sugi Predict

Sugi Predict / Compounds / SCHEMBL2247143

SCHEMBL2247143

SCHEMBL2247143

CC(=O)Nc1cc2c(cc1[N+](=O)[O-])OCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.46
▸ NPSR1 Q6W5P4 3/20 0.46
▸ HTT P42858 3/20 0.44
▸ ALDH1A1 P00352 6/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ KMT2A Q03164 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ POLB P06746 3/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ GALR2 O43603 1/20 0.40
▸ MITF O75030 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ XBP1 P17861 1/20 0.40
▸ CCR6 P51684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30860757 0.95 ALDH1A1 (0.47) MAPTNPSR1HTTALDH1A1KDM4E
SCHEMBL2241580 0.92 MAPT (0.44) MAPTNPSR1HTTALDH1A1KDM4E
SCHEMBL29739434 0.92 MAPT (0.44) MAPTNPSR1HTTALDH1A1KDM4E
Carbamic Acid SCHEMBL26633282 0.90 MAPT (0.41) MAPTNPSR1HTTALDH1A1KDM4E
SCHEMBL8089423 0.88 KDM4E (0.44) MAPTNPSR1ALDH1A1KDM4EHSD17B10
SCHEMBL14141980 0.86 ALDH1A1 (0.59) MAPTNPSR1HTTALDH1A1KDM4E
SCHEMBL10843250 0.83 ALDH1A1 (0.52) MAPTNPSR1HTTALDH1A1KDM4E
SCHEMBL10842362 0.82 MAPT (0.44) MAPTNPSR1HTTALDH1A1KDM4E
SCHEMBL2245461 0.80 KMT2A (0.51) MAPTNPSR1HTTALDH1A1KDM4E
SCHEMBL2246040 0.79 MAPT (0.51) MAPTNPSR1HTTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115843293-B Tricyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2025-01-24 — — CN disclosed
CN-115843293-A Tricyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-03-24 — — CN disclosed
WO-2022267930-A1 TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2022-12-29 — — WO disclosed
WO-2022121805-A1 FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF 成都康弘药业集团股份有限公司 2022-06-16 — — WO disclosed
CN-114591293-A Fused ring compound as Nav1.8 inhibitor and application thereof 成都康弘药业集团股份有限公司 2022-06-07 — — CN disclosed
EP-2532665-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF XUANZHU PHARMA CO LTD (CN) 2016-09-07 — — EP disclosed
EP-2532665-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF XUANZHU PHARMA CO LTD (CN) 2016-09-07 — — EP disclosed
US-20160176892-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) 2016-06-23 — — US disclosed
US-20160176892-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) 2016-06-23 — — US disclosed
US-9315513-B2 Benzimidazole derivatives and their pharmaceutical compositions and uses Xuanzhu Pharma Co., Ltd. (CN) 2016-04-19 — — US disclosed
WO-2008147812-A2 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-12-04 — — WO disclosed
WO-2008147812-A2 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-12-04 — — WO disclosed
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 — — US disclosed
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 — — US disclosed
WO-2008101247-A2 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 — — WO disclosed
WO-2008101247-A2 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 — — WO disclosed
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2008-08-21 — — US disclosed
EP-0059884-B1 BENZOFURANE DERIVATIVES, THEIR PREPARATION AND USE SCHERING AKTIENGESELLSCHAFT (DE) 1985-05-22 — — EP disclosed
US-4411910-A Benzofuran derivatives and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 1983-10-25 — — US disclosed
EP-0059884-A1 Benzofurane derivatives, their preparation and use SCHERING AKTIENGESELLSCHAFT (DE) 1982-09-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176892-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES F12, HRH2, H1-3 MAPT 4289/4885NPSR1 3572/4885HTT 3160/4885
US-20080200471-A1 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR1B, HTR1A MAPT 4295/4885NPSR1 40/4885HTT 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.